强化化疗联合或不联合达沙替尼治疗核心结合因子急性髓系白血病的3期研究
这项随机、开放标签3期试验纳入202例成人核心结合因子急性髓系白血病(CBF-AML)患者,比较强化化疗联合或不联合多激酶抑制剂达沙替尼的疗效。研究组严重不良事件发生率更高(64% vs 36%)。
要点
- 在强化化疗基础上加用达沙替尼未能改善CBF-AML患者的生存结局。
- 达沙替尼组严重不良事件发生率高于标准组(64% vs 36%)。
- 按年龄、CBF-AML类型和KIT突变状态亚组分析,EFS均无显著差异。
核心结论
- 在CBF-AML患者中,强化化疗联合达沙替尼未能改善生存 outcomes,且与毒性增加相关。
研究设计与样本
- 随机、开放标签3期试验,共202例成人CBF-AML患者随机分配至标准组(n=102)和达沙替尼组(n=100)。
- 患者接受「3+7」诱导治疗,随后4周期大剂量阿糖胞苷;研究组在诱导第8-21天、巩固周期第6-28天每日给予达沙替尼100 mg,后续12个月单药达沙替尼100 mg每日。
- 中位年龄49岁(范围18-77);94例为t(8;21),108例为inv(16)/t(16;16);58例(28.7%)携带KIT共突变。
主要发现
- 次要终点(总生存、无复发生存、累积复发率)在两组间亦无显著差异。
- 按年龄、CBF-AML类型和KIT突变状态亚组分析,EFS均无显著差异。
- 研究组严重不良事件发生率为64%,标准组为36%。
临床怎么用
- 对于CBF-AML成人患者,不建议在强化化疗基础上常规加用达沙替尼,因未改善生存且增加毒性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Core-binding factor acute myeloid leukemia (CBF-AML) is associated with KIT mutations and deregulated expression of KIT. We report results from the randomized, open-label, phase 3 trial of intensive chemotherapy with or without the multikinase inhibitor dasatinib in adult patients with CBF-AML. Patients received "3+7" induction therapy, followed by 4 cycles of high-dose cytarabine; in the investigational arm, patients received dasatinib 100 mg daily on days 8 to 21 in induction, and on days 6 to 28 in consolidation cycles, followed by 12-month single-agent dasatinib 100 mg daily. Primary end point was event-free survival (EFS). Secondary end points included overall survival, relapse-free survival, and cumulative incidence of relapse. A total of 202 patients were randomly assigned to the standard arm (n = 102) and to the dasatinib arm (n = 100). Median age was 49 years (range, 18-77); 94 patients had t(8;21), 108 had inv(16)/t(16;16); and 58 (28.7%) patients had a KIT comutation. There was no statistically significant difference in EFS (hazard ratio, 0.92; 95% confidence interval, 0.63-1.33; P = .66) or secondary end points between treatment arms. There was also no significant difference in EFS in subgroup analyses according to age, CBF-AML type, and KIT mutation status. The incidence of serious adverse events was higher in the investigational arm (64%) than in the standard arm (36%). In patients with CBF-AML, the addition of dasatinib to intensive chemotherapy failed to improve survival outcomes. The addition of dasatinib was associated with an increase in toxicity. This trial was registered at www.ClinicalTrials.gov as NCT02013648.
引用
- Döhner H, Späth D, Saadati M, et al. A phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia. Blood. 2026. PMID: 41490515. doi:10.1182/blood.2025030722
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。